Option chain shows key data for Indaptus Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Indaptus Therapeutics.

Indaptus Therapeutics (NASDAQ:INDP) Stock, Option Chain

Indaptus Therapeutics

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Screenshot 2025-04-21 at 5.37.26 PM

Biotech

General

INDP

Bacteria: The Surprising Tool In The Fight Against Cancer – And How Indaptus Is Taking It Further

News

Health Care

Market-Moving Exclusives

Exclusives

Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment.

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene&#39;s Cancer Drug For Advanced Solid Tumors

Screenshot 2025-03-17 at 5.34.34 PM

Aggressive Cancers In Young People Are On The Rise – Can The Immune System Fight Back Better? Indaptus Therapeutics Thinks So

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics Inc

Press Releases

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Legal

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Registration Is Now Open For Tribe Public's Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Earnings

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Analyst Ratings

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

180 Life Sciences

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

GT Biopharma

HCW Biologics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

MetaVia

Mainz Biomed

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

Soligenix

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Turnstone Biologics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Indaptus Therapeutics

Indaptus Therapeutics (INDP) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell